ReviewFEBS open bio2022
Influenza antivirals and animal models.
Review in FEBS open bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Associations of oseltamivir with neuropsychiatric and behavioral adverse events: A systematic review and meta-analysis.Journal of managed care & specialty pharmacy · 2025Pooled it
- Syrian hamster is a valuable animal model for evaluating the transmissibility of emerging influenza viruses.Emerging microbes & infections · 2026Article
- Generation of an Induced Pluripotent Stem Cell-Derived Alveolar Type II In Vitro Model to Study Influenza A Virus Infection and Drug Treatments.Advanced healthcare materials · 2026Article
- Review
- Modeling viral shedding and symptom outcomes in oseltamivir-treated experimental influenza infection.PloS one · 2026Article
- Single-cell dissection of avian (chicken) H1N1 influenza virus coinfection dynamics in mammalian (mouse) and avian (chicken) hosts.Acta biochimica et biophysica Sinica · 2025Article
- Mucosal delivery of influenza antigens using a replication deficient adenovirus supports broadly reactive antibody responses and heterologous viral immunity in the respiratory tract of animals.bioRxiv : the preprint server for biology · 2025Article
- Study on the Mechanism of RuHaoDaShi Granules in Treating H1N1 Viral Pneumonia Based on Network Pharmacology and Experimental Validation.Pathogens (Basel, Switzerland) · 2025Article
- A Deep Learning Framework for Using Search Engine Data to Predict Influenza-Like Illness and Distinguish Epidemic and Nonepidemic Seasons: Multifeature Time Series Analysis.Journal of medical Internet research · 2025Article
- The application and discovery of animal models in enterovirus research.Archives of virology · 2025Review
- ChatGPT-Assisted Deep Learning Models for Influenza-Like Illness Prediction in Mainland China: Time Series Analysis.Journal of medical Internet research · 2025Article
- Screening of neurotransmitter receptor modulators reveals novel inhibitors of influenza virus replication.Frontiers in cellular and infection microbiology · 2025Article
- Pandemic preparedness through vaccine development for avian influenza viruses.Human vaccines & immunotherapeutics · 2024Review
- Triton X-100-treated virus-based ELLA demonstrates discordant antigenic evolution of influenza B virus hemagglutinin and neuraminidase.Journal of virology · 2024Article
- Antiviral drugs in animal-derived matrices: A review.Heliyon · 2024Review
- Influenza B Virus Vaccine Innovation through Computational Design.Pathogens (Basel, Switzerland) · 2024Review
- Viral airway injury promotes cell engraftment in an in vitro model of cystic fibrosis cell therapy.American journal of physiology. Lung cellular and molecular physiology · 2024Article
- The prediction of influenza-like illness using national influenza surveillance data and Baidu query data.BMC public health · 2024Article
- Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism.Frontiers in pharmacology · 2024Article
- Exploring the inhibition of the soluble lytic transglycosylase Cj0843c of Campylobacter jejuni via targeting different sites with different scaffolds.Protein science : a publication of the Protein Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Influenza A and B viruses are among the most prominent human respiratory pathogens. About 3-5 million severe cases of influenza are associated with 300 000-650 000 deaths per year globally. Antivirals effective at reducing morbidity and mortality are part of the first line of defense against influenza. FDA-approved antiviral drugs currently include adamantanes (rimantadine and amantadine), neuraminidase inhibitors (NAI; peramivir, zanamivir, and oseltamivir), and the PA endonuclease inhibitor (baloxavir). Mutations associated with antiviral resistance are common and highlight the need for further improvement and development of novel anti-influenza drugs. A summary is provided for the current knowledge of the approved influenza antivirals and antivirals strategies under evaluation in clinical trials. Preclinical evaluations of novel compounds effective against influenza in different animal models are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.